[1]. Cheng F.#, Zhu L. #, Schwaneberg U. Directed evolution 2.0: improving and deciphering enzyme properties. Chemical Communication, 2015, 51(48), 9760-9772. (co-first author)
[2]. Cheng F., Kardashliev T., Pitzler C., Shehzad A, Lue H., Bernhagen J, Zhu L.*, Schwaneberg U.* A competitive flow cytometry screening system for arginine-metabolizing enzyme in cancer treatment. ACS Synthetic Biology, 2015, 4(7):768-775. (co-first author)
[3]. Machedjoua J., Fulton A., Zhu L., Ankera C., Bocola M., Jaeger K. and Schwaneberg U. Towards understanding of directed evolution: >52% amino acid positions contributed to ionic liquid resistance of Bacillus subtilis lipase A (BSLA). ChemBioChem, 2015, 16(6), 937-945.
[4]. Fulton A., Machedjoua J., Skoczinski P., Wilhelm S., Zhu L., Schwaneberg U. and Jaeger K. Exploring the protein stability landscape: Bacillus subtilis lipase A as a model for detergent tolerance. ChemBioChem, 2015, 16(6):930-6.
[5]. Zhu L., Cheng F., Piatkowski V. and Schwaneberg U. Protein engineering of PpADI for improved thermostability. ChemBioChem. 2014, 15(2), 276-83.
[6]. Cheng F., Zhu L.*, Lue H., Bernhagen J, Schwaneberg U.* Directed arginine deiminase evolution for efficient inhibition of arginine-auxotrophic melanomas. Applied Microbiology and Biotechnology, 2014, 99(3), 1237-1247. (co-corresponding author)
[7]. Rijn P., Tutus M., Kathrein C., Zhu L., Wessling M., Schwaneberg U., and Böker A. Challenges and Advances in the Field of Self-Assembled Membranes, Chemical Society Reviews. 2013, 42(16):6578-6592.
[8]. Liu H., Zhu L., Bocola M., Chen N., Spiess A. C. and Schwaneberg U. Directed laccase evolution for improved ionic liquid resistance. Green Chemistry, 2013, 15, 1348-1355.
[9]. Philippart F., Arlt M., Gotzen S., Tenne S. J., Bocola M., Chen H. H., Zhu L., Schwaneberg U. and Okuda J. A hybrid ring-opening metathesis polymerization catalyst based on engineered ß-barrel protein FhuA. Chemistry a Euopean Journal. 2013, 19(41), 13865–13871.
[10]. Ni Y., Liu Y., Schwaneberg U., Zhu L., Li N., Li L., Sun Z. Rapid evolution of arginine deiminase for improved anti-tumor activity. Applied Microbiology Biotechnology. 2011, 90(1):193-201.
[11]. Zhu L., Rajni V., Roccatano D., Ni Y., Sun Z., and Schwaneberg U. A potential antitumor drug (arginine deiminase) reengineered for efficient operation under physiological conditions. ChemBioChem. 2010, 11(16):2294-301.
[12]. Zhu L., Tee K., Roccatano D., Sonmez B, Ni Y., Sun Z., and Schwaneberg U. Directed evolution of an antitumor drug (arginine deiminase PpADI) for increased activity at physiological pH. ChemBioChem. 2010, 11, 691-697.
[13]. Ni Y., Li Z., Sun Z., Zheng P., Liu Y. Zhu L., Schwaneberg U. Expression of arginine deiminase from Pseudomonas plecoglossicida CGMCC2039 in Escherichia coli and its anti-tumor activity. Current Microbiology. 2009, 58(6):593-8.
[14]. Liu Y., Zheng P, Sun Z., Ni Y., Dong J. and Zhu L. Economical succinic acid production from cane molasses by Actinobacillus succinogenes. Bioresource Technology. 2008, 99(6): 1736-1742.
[15]. Zhao L., Sun Z., Zheng P., Zhu L. Biotransformation of isoeugenol to vanillin by a novel strain, Bacillus fusiformis. Biotechnology Letters. 2005, 27, 1505-1509.
Patents
[1] Schwaneberg U., Zhu L. Directed evolution of arginine deiminase for increased activity at physiological pH, Germany,EP2295560A1 (WO 2011029696 A1), 2011-03-17..